Infections, Papillomavirus: Clinical Trials

61 completed, 2 terminated, 2 withdrawn. 39 Phase 3, 11 Phase 2, 3 Phase 1, 2 Phase 4.

By phase and status

Phase	Trials	Status
Phase 3	39	Completed 37, Withdrawn 2
Phase 2	11	Completed 11
Phase 1	3	Completed 3
Phase 4	2	Completed 2

Follow Infections, Papillomavirus: new trials by email Literature Review of Infections, Papillomavirus trials Research Report on Infections, Papillomavirus

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years Cervarix™, Havrix - Infections, Papillomavirus	Phase 3	Withdrawn	GlaxoSmithKline		2015-02-01	2015-07-20
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study Blood sampling - Infections, Papillomavirus	Phase 3	Withdrawn	GlaxoSmithKline		2015-01-01	2015-07-20
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Data collection - Infections, Papillomavirus		Completed	GlaxoSmithKline	1053	2013-10-01	2016-12-26
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK Data Collection, Cervarix - Infections, Papillomavirus		Completed	GlaxoSmithKline	1046	2012-11-01	2013-09-30
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old Cervarix, Priorix, Infanrix - Infections, Papillomavirus	Phase 3	Completed	GlaxoSmithKline	148	2012-10-15	2020-04-10
Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study CervarixTM (GSK580299) - Infections, Papillomavirus	Phase 3	Completed	GlaxoSmithKline	164	2012-05-29	2018-07-12
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females Cervarix, Gardasil, Placebo - Infections, Papillomavirus	Phase 3	Completed	GlaxoSmithKline	1079	2011-11-21	2019-11-15
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada Data collection - Infections, Papillomavirus		Terminated	GlaxoSmithKline	2	2011-09-26	2018-07-26
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects Gynaecological follow-up, Cervarix, Placebo control - Infections, Papillomavirus	Phase 3	Completed	GlaxoSmithKline	34	2011-09-12	2019-10-30
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls GSK Biologicals' HPV vaccine 580299 - Infections, Papillomavirus	Phase 3	Completed	GlaxoSmithKline	1447	2011-06-29	2020-06-09
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study GSK580299 (Cervarix) - Infections, Papillomavirus	Phase 3	Completed	GlaxoSmithKline	137	2011-04-01	2019-06-19
Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) GSK580299 (CervarixTM), Engerix-BTM - Infections, Papillomavirus	Phase 3	Completed	GlaxoSmithKline	1212	2011-02-17	2018-08-17
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study GSK580299 (Cervarix) - Infections, Papillomavirus	Phase 3	Completed	GlaxoSmithKline	199	2011-01-24	2019-11-13
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil) - Infections, Papillomavirus, Papillomavirus Vaccines	Phase 4	Completed	GlaxoSmithKline	873	2010-10-26	2020-07-21
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination Data collection - Infections, Papillomavirus		Completed	GlaxoSmithKline	1516	2010-10-01	2014-12-02
Drug Use Investigation for Cervarix® Cervarix® - Infections, Papillomavirus		Completed	GlaxoSmithKline	1230	2010-09-01	2015-01-26
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females Cervarix., Data collection - Infections, Papillomavirus		Completed	GlaxoSmithKline	3091	2010-07-01	2018-07-23
Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in Norway Cancer Registry of Norway (database) - Infections, Papillomavirus		Terminated	GlaxoSmithKline	410	2010-06-01	2015-04-20
Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia Cervical samples, Data collection - Infections, Papillomavirus, Cervical Cancer		Completed	GlaxoSmithKline	420	2010-04-01	2012-11-22
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects CervarixTM, Control - Infections, Papillomavirus	Phase 3	Completed	GlaxoSmithKline	750	2009-10-24	2018-08-17

Showing 20 of 65. Sign in to see all of them.

Narrower conditions

Papillomavirus Infections (65)  ·  Uterine Cervical Neoplasms (26)  ·  Autoimmune Diseases (3)  ·  Virus Diseases (3)  ·  Abortion, Spontaneous (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Hepatitis B (1)  ·  Meningitis (1)  ·  Tetanus (1)  ·  Uterine Cervical Dysplasia (1)  ·  Whooping Cough (1)

Broader conditions

Communicable Diseases (65)  ·  DNA Virus Infections (65)  ·  Disease Attributes (65)  ·  Genital Diseases (65)  ·  Infections (65)  ·  Pathologic Processes (65)  ·  Pathological Conditions, Signs and Symptoms (65)  ·  Sexually Transmitted Diseases (65)  ·  Sexually Transmitted Diseases, Viral (65)  ·  Tumor Virus Infections (65)  ·  Urogenital Diseases (65)  ·  Virus Diseases (62)  ·  Female Urogenital Diseases and Pregnancy Complications (29)  ·  Female Urogenital Diseases (27)  ·  Genital Diseases, Female (27)

Interventions

human papillomavirus vaccine, L1 type 16, 18 (34)  ·  Data Collection (8)  ·  Papillomavirus Vaccines (6)  ·  Blood Specimen Collection (5)  ·  Engerix-B (3)  ·  Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (3)  ·  halofantrine (2)  ·  AKAP13 protein, human (1)  ·  Adjuvants, Pharmaceutic (1)  ·  Chorionic Villi Sampling (1)  ·  DTPa-HBV-IPV combined vaccine (1)  ·  Diphtheria-Tetanus-acellular Pertussis Vaccines (1)  ·  Hepatitis A Vaccines (1)  ·  Measles-Mumps-Rubella Vaccine (1)  ·  Pentetic Acid (1)

Sponsors

GlaxoSmithKline (65)

Countries

United States (14)  ·  Canada (11)  ·  Germany (9)  ·  Brazil (7)  ·  Belgium (6)  ·  Taiwan (6)  ·  Thailand (6)  ·  Australia (5)  ·  Finland (5)  ·  Netherlands (5)  ·  United Kingdom (5)  ·  China (4)  ·  Italy (4)  ·  Russia (4)  ·  Singapore (4)

Results publications

PMID 41276263, PMID 31824976, PMID 24731816, PMID 25424785, PMID 25424918, PMID 25424783, PMID 27566633, PMID 31464859, PMID 34939897, PMID 35149535, PMID 17602732, PMID 19586656, PMID 20113920, PMID 20197322, PMID 20413076, PMID 20606533, PMID 21273939, PMID 21817954, PMID 21858807, PMID 22075170, PMID 22075171, PMID 22265115, PMID 22327492, PMID 22940493, PMID 23063422, PMID 24092907, PMID 24092908, PMID 24138429, PMID 24188719, PMID 24260180, PMID 24576907, PMID 24610876, PMID 24631451, PMID 24674663, PMID 25208608, PMID 25496614, PMID 25540273, PMID 25593103, PMID 25651922, PMID 25927224, PMID 26176261, PMID 26685704, PMID 28266092, PMID 29055031, PMID 29845626, PMID 30715452, PMID 31273942, PMID 31305011, PMID 31511286, PMID 31736068

NIH funding

2004 (3), 2005 (2), 2008 (2), 2009 (2), 2014 (1)